Cancer de Prostate, déprivation androgénique, et risques d’infection par la COVID-19 : revue systématique et méta-analyse

INTRODUCTION: Male gender has been shown to be a risk factor for COVID-19 infection, and men are more likely to develop severe disease. The aim of this study was to evaluate the effect of androgen deprivation therapy (ADT) on the incidence of infection and severity of SARS-CoV-2 in prostate cancer patients. METHODS: A systematic review and meta-analysis were performed after searching PubMed, Scopus, and ClinicalTrial.org databases, between January 2020 and March 2022. Analyses were interpreted through forest plots for the following parameters: risk of infection, hospitalization, intensive care admission, and SARS-CoV-2-related death, with random or fixed-effects models. RESULTS: Fifteen articles were included in the systematic review and ten in the meta-analysis. Seven studies evaluated risk of infection in patients on ADT: OR = 1.11 (95 % IC : [0.48–2.58] ; P = 0.81). Six studies evaluated the risk of hospitalization in patients on ADT: TDA : OR = 1.58 (95 % IC : [0.94–2.64] ; P = 0.08). Seven studies evaluated risk of ICU admission in patients on ADT: OR = 0.90 (95 % IC : [0.71–1.13] ; P = 0.37). Nine studies evaluated mortality risk in patients on ADT: OR = 1.07 (95 % IC : [0.61–1.87] ; P = 0.82). CONCLUSION: ADT does not protect against SARS-CoV-2 in prostate cancer patients, nor does it protect against hospitalization, ICU admission, or mortality. These results remain questionable given the retrospective nature of the majority of studies included in our meta-analysis.